Bonducellin has anti-inflammatory activities, it can significantly and dose-dependently inhibit the inflammatory mediators; nitric oxide (NO), and cytokines [tumor necrosis factor (TNF)-alpha and interleukin (IL)-12. Bonducellin shows weak antimalarial activity against Plasmodium falciparum with the IC50 value of 26 uM; it also shows weak antiproliferative against A2780 human ovarian cancer cell line , with the IC50 value of 10.6 uM. Bonducellin shows modulation in the MIC of EtBr by eight fold at a concentration of 62.5 mg/L and also shows significant efflux pump inhibitory activity.